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1. Introduction 
1.1. Glucocorticoids therapeutic effects  
Synthetic glucocorticoids (GCs) as effective anti-inflammatory therapeutics are the most 
widely prescribed drugs in the clinic for the treatment of various conditions including 
asthma, ulcerative colitis, rheumatoid arthritis and hay fever [1-4]. Glucocorticoids in some 
cases exert effective anti-neoplastic effects in cancers of blood origin such as acute 
lymphocytic leukaemia (ALL) as a result of the ability of these hormones to induce cell 
death in blood cells [1-3]. Resistance to glucocorticoid mediated cell death remains one of 
the main reasons for inefficient therapy [1] and usually occurs upon prolonged 
glucocorticoid treatment [2] compromising significantly the success of therapy [3]. The 
molecular mechanisms mediating glucocorticoid dependent initiation of programmed cell 
death have been extensively investigated but there are several aspects of these pathways 
that have not yet been clearly defined. Since understanding of these mechanisms would be 
beneficial towards improving the glucocorticoids therapeutic efficacy further research 
exemplifying resistance to glucocrticoid treatment is necessary. 
Glucocorticoids (GCs) exert their anti-inflammatory and immunosuppressive effects 
through either genomic or non-genomic mechanisms. Non-genomic early effects of 
glucocorticoids are induced in tissues bearing high concentrations of this hormone by 
interfering with the physicochemical properties of plasma and mitochondrial membranes 
[4]. In particular, glucocorticoids intercalate into these membranes altering lipid 
peroxidation and membrane permeability [5]. In addition, non-genomic effects of 
glucocorticoids include early suppression of the mitogen-activated protein kinase (MAPK) 
and hence inflammatory signal transduction cascades such as calcium influx, phagocytosis, 
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neutrophil degranulation and cellular adhesion [6, 7, 8, 9, 10, 11]. The non genomic effects of 
GCs are very important in delivering short-term therapeutic benefits to asthma and 
rheumatoid arthritis which are diseases characterized by high inflammatory state [12].  
2. Mechanisms of GC-mediated cell death  
At the molecular level GCs exert their function by interacting with their intracellular GC 
receptor (GR), which is a hormone responsive transcription factor that modulates gene 
expression of its target genes [13]. Glucocorticoids activate the cellular death machinery 
through transcriptional and non-transcriptional pathways by means of either the extrinsic or 
intrinsic pathway of apoptosis [3, 14, 15, 16].  
The extrinsic pathway is induced upon activation of the membrane death receptors such as 
the tumour necrosis factor (TNF) receptor superfamily, member 6, Fas-Ligand (Fas-L) [17]. 
The binding of Fas-L leads to the activation of effector caspases (caspases 3, 6 and 7) via the 
activation of inducer caspases, particularly caspase 8 [18]. Evidence that glucocorticoids are 
involved in the regulation of the extrinsic pathway of apoptosis has been provided by 
observations suggesting that glucocorticoids inhibit the induction of Fas-L (but not Fas) 
signalling in T-cell hybridomas [19, 20]. On the contrary inhibition of the extrinsic pathway 
using the caspase 8 inhibitor cytokine response modifier A (crmA) in pre-B leukemic cells 
treated with glucocorticoids indicated that GR does not initiate apoptosis in these cells 
through the extrinsic pathway [21, 22]. The involvement of the intrinsic pathway, on the 
other hand, in the glucocorticoid mediated cell death and in particular the regulation of the 
balance between pro- and anti-apoptotic members of the bcl-2 family has been shown in 
hepatocytes, small cell lung cancer, primary ALL lymphoblasts and animal systems [23, 24].  
The intrinsic pathway of cell death is stimulated in response to intracellular signals, and 
involves mitochondria releasing pro-apoptotic molecules, formation of the apoptosome and 
activation of the effector caspases via the initiator caspase 9 [25]. The balance between pro- 
and anti-apoptotic members of the B cell leukaemia/ lymphoma 2-like (Bcl-2) family plays a 
crucial role in the execution of apoptosis by glucocorticoids through the intrinsic pathway 
[18]. In particular, glucocorticoids regulate the expression of various genes involved in the 
initiation of apoptosis, including the pro-apoptotic Bcl-2 family member BCL2-like 11 (Bim) 
[22, 26, 27, 28]. Transactivation of Bim results in the activation of the Bcl-2–associated X 
protein (Bax) and the Bcl2-antagonist/killer 1 (Bak), which mediate the disruption of 
mitochondrial membrane potential and the release of cytochrome c into the cytosol [29]. 
Cytochrome c then binds to its adaptor apoptotic protease activating factor (Apaf-1), thereby 
activating caspase 9 and several effector caspases [30]. Furthermore, mitochondria mediate 
the generation of reactive oxygen species (ROS), which may potentially have an add-on 
effect on glucocorticoid-induced apoptosis [31]. 
In some cases glucocorticoids induce apoptosis by using both the intrinsic and the extrinsic 
pathways. This is mediated by the cleaved caspase-8 which subsequently leads to activation 
of the pro-apoptotic member of the Bcl-2 family, Bcl-2 homology 3 (BH3) interacting domain 
death agonist (Bid) [32]. The C-terminal truncated Bid (t-Bid) activates caspase 9 and the 
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effector caspases 3, 6 and 7 [33]. The intrinsic and extrinsic pathways through which 
glucocorticoids induce apoptosis in cells responsive to these hormones are illustrated in 
Figure 1. 
 
Figure 1. Schematic diagram indicating the extrinsic and intrinsic pathways through which 
glucocorticoids regulate apoptosis. 
Several mechanisms have been proposed to explain the evasion of glucocorticoid mediated 
apoptosis in resistant cells [34]. These include alterations in the activity of the glucocorticoid 
receptor [35, 36] either due to changes in GR protein levels, presence of multiple GR 
variants, or post-translational modifications. GR induces apoptosis by directly modulating 
the expression of genes involved in cell survival/apoptosis [18, 37], or affecting gene 
networks involved in stress signalling resulting in an apoptotic stimulus [36, 38]. 
3. GR transcriptional activity is necessary for its pro-apoptotic function  
Glucocorticoid induced apoptosis depends on the presence of adequate amounts of 
transcriptionally active GR [34, 39, 40, 41, 42]. It has also been shown that the presence of 
specific GR splicing variants is necessary for the stimulation of GCs dependent apoptosis 
[3]. Alternative hGR splicing produces two receptor variants called GRα and GRβ, which 
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are highly homologous differing by 50 additional amino acids present in the carboxy 
terminal region of GRα [43]. GRα is mainly cytoplasmic, and exhibits the typical 
glucocorticoid receptor function in terms of ligand-dependent transcriptional regulation and 
as such it is the major functional GR isoform therefore its expression is crucial for cellular 
sensitivity to GCs [3]. GRβ on the other hand, does not bind ligands, and exerts a dominant 
negative effect on GRα transcriptional activity [43, 44, 45]. In clinical studies reduced GRα 
protein levels correlate with resistance to GCs induced apoptosis and disadvantageous 
prognosis in ALL [3]. Additional indication that GR transcriptional activity is necessary for 
the initiation of the GCs mediated apoptosis has been provided by the observation that 
various mutations affecting GR transcriptional activity have been detected in patients 
exhibiting resistance to glucocorticoids treatment [2, 46]. Furthermore, prolonged 
glucocorticoid treatment significantly reduces GRα expression [47], whereas GRβ expression 
is not affected [48]. 
4. GR dependent regulation of the balance between pro- and anti-
apoptotic Bcl-2 family members 
B cell leukaemia/ lymphoma 2-like (Bcl-2) family members are categorised into pro- and 
anti-apoptotic and the balance between the levels of these two types of proteins 
determines the cellular fate (survival or death) [23]. The involvement of the Bcl-2 family 
members in the glucocorticoid-induced apoptosis has been shown in cellular and animal 
studies [49]. For example, the expression of the anti-apoptotic Bcl-2 family member in 
glucocorticoid-sensitive thymocytes is lower compared to that in glucocorticoid-resistant 
ones [2], and overexpression of the anti-apoptotic Bcl-2 and B-cell lymphoma-extra large 
(Bcl-xL) in human ALL prevents glucocorticoids induced apoptosis [50, 51, 52, 53] 
whereas knock down of the pro-apoptotic member Bim confers resistance to 
dexamethasone mediated apoptosis [54]. Furthermore, over-expression of the pro-
apoptotic Bax [55] and knock down of the myeloid cell leukemia sequence 1 (Mcl-1) 
sensitises ALL cells to glucocorticoid treatment [56]. We have shown recently that the 
balance between Mcl-1 and phorbol-12-myristate-13-acetate-induced protein 1 (Noxa) is a 
determinant of resistance / sensitivity of ALL cells to glucocorticoid-induced apoptosis 
[57, 58]. Several studies have shown that the pro-apoptotic Bcl-2 family member Bim plays 
crucial role in the glucocorticoid-induced apoptosis but further investigation is required 
to define the detailed molecular mechanisms of this process. Up-regulated Bim has been 
observed in various cell lines upon glucocorticoid treatment including ALL cells [59], 
primary chronic lymphocytic leukaemia (CLL) cells [27], and some patients with ALL [60]. 
Moreover knockout of Bim, p53 up-regulated modulator of apoptosis (Puma) or Noxa, or 
double knockouts of Bax and Bak confer resistance to glucocorticoid-mediated apoptosis 
in thymocytes [61, 62, 63]. Overall the balance of the levels between pro- and anti-
apoptotic Bcl-2 family members has been recognised as a crucial factor in the 
determination of lymphocytes survival or death and induction of the glucocorticoid 
dependent programmed cell death.  
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Gene Protein Function Role in glucocorticoid-induced apoptosis 
Bcl2 
B-cell Lymphoma 2 
(Bcl-2) 
Anti-
apoptotic 
Over-expression of Bcl-2 in human ALL cells 
prevents glucocorticoids induced apoptosis 
[41, 64] 
BCL-xL 
 B-cell lymphoma-
extra large (Bcl-xL) 
Anti-
apoptotic 
Over-expression of Bcl-xL in human ALL cells 
prevents glucocorticoids induced apoptosis 
[23] 
BCL2L11 BCL2 Like 11 (Bim) Pro-apoptotic 
Knock down of Bim confers resistance of ALL 
cells to glucocorticoid-induced apoptosis [65]. 
Upregulation of Bim sensitizes cells to 
glucocorticoid-induced apoptosis [27, 66]. 
Mcl1 
Myeloid cell 
leukemia 1 (Mcl-1) 
Anti-
apoptotic 
Knock down of Mcl-1 sensitises ALL cells to 
glucocorticoids apoptotic effect [56]. 
Phorbol-12-
myristate-13-
acetate-
induced 
protein 1 
Phorbol-12-
myristate-13-
acetate-induced 
protein 1 (Noxa) 
Pro-apoptotic 
Noxa regulates the Mcl-1 protein stability and 
Noxa/Mcl-1 balance determines cell survival 
or death [57].  
p53 up-
regulated 
modulator of 
apoptosis 
p53 upregulated 
modulator of 
apoptosis (Puma) 
Pro-apoptotic 
Puma facilitates glucocorticoid-induced 
apoptosis of lymphocytes [62, 65]. 
Bax 
Bcl-2–associated X 
(Bax) 
Pro-apoptotic 
Bax protein regulates glucocorticoid induced 
apoptosis in thymocytes [67]. Double 
knockouts of Bax and Bak confer resistance to 
glucocorticoid-induced apoptosis in 
thymocytes [68]. 
Bak 
Bcl-2 homologous 
antagonist/killer 
(Bak) 
Pro-apoptotic 
Double knockouts of Bax and Bak confer 
resistance to glucocorticoid-mediated 
apoptosis in thymocytes [68]. 
Table 1. Pro- and anti-apoptotic Bcl-2 family members implicated in the glucocorticoids induced 
apoptosis 
5. Autophagy 
Autophagy is a several steps process leading to cellular degradation of unfolded or 
aggregated proteins and organelles in response to diverse types of stress such as starvation 
or metabolic stress and is an essential mechanism contributing to survival, differentiation, 
development, and homeostasis. Autophagy protects against chronic inflammatory 
conditions occurring in a variety of pathological situations such as infections, cardiovascular 
disease, neurodegenaration, inflammatory bowel diseases, aging and cancer [69]. 
Autophagy has been shown to be involved in prosurvival processes facilitating resistance of 
cancer cells to chemotherapy as well as under certain conditions in apoptosis [70]. Taking 
into account the fact that autophagy is prosurvival in addition to reports indicating that 
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inhibitors of autophagy re-sensitise cancer cells to anticancer therapeutics [70, 71] as well as 
that autophagy is associated with inflammation and resistance to cancer therapy 
investigators were prompted to study the role of autophagy in the resistance to 
glucocorticoid induced apoptosis in ALL [72, 73]. These studies have indicated that 
dexamethasone induces autophagy before the initiation of apoptosis in ALL cells and in 
actual fact autophagy is a prerequisite for the efficient execution of apoptosis mediated by 
dexamethasone [72, 73]. More recently the molecular mechanism by which activation of 
autophagy overturns glucocorticoid resistance has been elucidated [74] signifying the 
important role of the autophagy inducer beclin-1 and the anti-apoptotic Bcl-2 family 
member Mcl-1 [74, 75]. Furthermore the inhibition of caspase by selective degradation of 
catalase and consequent generation of high concentrations of reactive oxygen species might 
be an alternative mechanism explaining the role of autophagy in dexamethasone induced 
apoptosis [76]. 
6. Post-translational modifications 
Post-translational modifications of GR are important in regulating its transcriptional 
activity, protein stability, binding of GR with other transcription factors or co-modulators 
and subcellular localisation, and for these reasons post-translational modifications are 
highly relevant to glucocorticoids therapeutic efficacy [77, 78, 79, 80, 81]. GR acetylation is 
cell type dependent and it is suggested to suppress the receptor’s transcriptional activity by 
reducing its ability to bind to the Glucocorticoid Responsive Elements (GREs) present in its 
target genes [82], or inhibit the ability of GR to translocate into the nucleus [83]. Regulation 
of GR transcriptional activity also takes place through ubiquitination and proteasomal 
degradation of the receptor upon ligand binding [84, 85]. Ubiquitination promotes 
interaction of GR with E2 conjugating and E3 ligase proteins causing turnover of the 
receptor and thus down-regulation of its transcriptional activity [85]. In support of these 
conclusions the proteasome inhibitor MG-132 enhances the transcriptional activity of GR 
[84]. Ligand-independent sumoylation has been shown to both inhibit [86, 87] as well as to 
stabilise and potentiate GR transcriptional activity [88]. Three sumoylation sites have been 
identified within the GR protein conferring GR transcriptional target selectivity [87]. We 
have recently reported that GR sumoylation is assisted by its phosphorylation at particular 
sites under certain conditions [89]. 
GR phosphorylation has been extensively investigated and several different kinases have 
been identified to induce phosphorylation of the receptor at distinct serine and threonine 
residues located within the N-terminal AF-1 transactivation domain of the receptor, either in 
the presence or in the absence of glucocorticoid hormone [90, 91, 92, 93, 94, 95]. S203 residue 
in human GR is targeted by cyclin/cyclin dependent kinase (CDK) complexes and is located 
mostly in the cytoplasm thus it is thought to be transcriptionally inactive [89, 95]. GR 
phosphorylated at S211 is transcriptionally active due to conformational changes which 
facilitate increased recruitment of the receptor to GRE-containing promoters and is a target 
for phosphorylation by both cyclin/CDK kinases and MAPK families depending on the cell 
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type [91, 96]. GR phosphorylation at S226 results in inhibition of the GR function, possibly 
due to increased GR nuclear export and is a result of JNK activation [80, 89, 97, 98]. Finally, 
phosphorylation of GR at S404 attenuates GR signalling and is due to GSK3 kinase 
activation [99]. We have recently reported that differential GR phosphorylation in the 
resistant CEM-C1-15 versus sensitive CEM-C7-14 ALL cells modulates GR transcriptional 
activity and target selectivity resulting in diverse pro- or anti-apoptotic Bcl-2 family 
members’ gene expression in the two cell lines [58]. In particular we have shown that GR 
phosphorylation at S211 is predominant in the glucocorticoid-sensitive CEM-C7-14 whereas 
GR phosphorylation at S226 by c-Jun N-terminal Kinase (JNK) occurs more frequently in the 
glucocorticoid-resistant CEM-C1-15 cells [58]. These observations lend support to the 
suggestion that different kinase pathways are responsible for GR phosphorylation in 
resistant versus sensitive cells to glucocorticoid induced apoptosis, thereby causing GR 
transcriptional inactivity in the resistant cell lines [58] concomitant Mcl-1 overexpression 
and hence resistance to GC treatment [56]. 
Apart from the differential expression of pro- and anti-apoptotic Bcl-2 family members [58] 
we have recently reported that GR isoforms localised in mitochondria are predominantly 
phosphorylated at serine 232 compared to serine 246 of the rat GR (corresponding to human 
GR Ser211 and Ser226 respectively) [96] possibly due to differential conformation of the two 
phosphoisoforms or diverse interaction patterns with components of the mitochondrial 
import machinery of the GR phosphorylated at serine 211 versus the GR phosphorylated at 
serine 226. These observations provide an additional potential explanation for the resistance 
of the CEM-C1-15 to glucocorticoids induced apoptosis in accord with recent reports 
indicating differential GR mitochondrial localisation in resistant compared to sensitive ALL 
cells to glucocorticoid induced apoptosis [93, 94, 95, 97]. 
7. Mitochondrial GR, glucocorticoids and cellular energy metabolism  
Glucocorticoid hormones directly affect mitochondrial membranes inducing loss of 
mitochondrial transmembrane potential, thereby affecting vital cellular processes mediated 
by the function of this organelle such as ATP generation via oxidative phosphorylation, 
regulation of calcium flux and apoptosis [98]. In addition, glucocorticoids exert their effects 
on mitochondrial biogenesis through the mitochondrial GR [97, 99, 100, 101]. The 
intracellular trafficking of the glucocorticoid receptor has been shown to play important role 
in glucocorticoid-induced apoptosis [97, 102]. The glucocorticoid receptor translocates to 
mitochondria [97, 100, 101, 102], in various cells including rat brain and various other 
tissues’ mitochondria [99], as well as lymphoma cells [97]. GR translocation to the nucleus 
occurs in both glucocorticoid-sensitive and glucocorticoid-resistant cells, whereas in 
contrast, GR translocation into mitochondria occurs only in the glucocorticoid-sensitive and 
not the resistant cells [97, 103]. The mechanisms by which GR translocates to mitochondria 
and its effects on the regulation of the expression of mitochondrially encoded genes have 
been partially elucidated [97, 100, 101, 102] and require further investigation. However, it is 
noteworthy that glucocorticoids modulate mitochondrial biogenesis and mitochondrial 
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energy production pathways by regulating the transcription of the mitochondrial genome 
[99, 100]. 
The process of programmed cell death is energy dependent requiring the precise 
coordination of several biochemical processes including the transcriptional regulation of 
the expression of genes encoding enzymatic components of the energy production 
pathways (oxidative phosphorylation (OXPHOS) and glycolysis) [29] and mutations 
affecting cellular energy production lead to defects in apoptosis and tumourigenesis [104, 
105, 106, 107, 108, 109]. In humans the OXPHOS pathway consists of five multi-subunit 
complexes whose components are encoded by genes located in both the nuclear and the 
mitochondrial genomes [110] supporting the notion that a transcription factor operating 
in both subcellular compartments could coordinate the expression of nuclear and 
mitochondrial genes ensuring appropriate stoichiometry and timely gene expression of 
the components of the respiratory chain [111]. In addition to the availability of the 
components encoded in the nuclear and the mitochondrial compartments an appropriate 
assembly mechanism of these subunits is essential for the functionality of the oxidative 
phosphorylation system [110]. One possible candidate transcription factor able to 
orchestrate nuclear and mitochondrial gene expression is the glucocorticoid receptor 
which mediates gene expression of both nuclear and mitochondrial encoded genes [98, 99, 
100, 102, 112, 113, 114, 115, 116].  
In fact, dexamethasone has been shown to affect energy metabolism and the balance 
between OXPHOS and glycolysis [117, 118]. Also, evidence has been recently presented 
indicating that changes in metabolic patterns and cellular proliferation are key aspects of 
resistance to GC mediated apoptosis in ALL [39]. Elevated glycolytic rate due to increased 
expression of genes involved in glucose metabolism are associated with resistance to 
glucocorticoid induced apoptosis and this resistance can be reversed by inhibitors of 
glycolysis in ALL [119, 120]. Moreover, glucocorticoid induced apoptosis is regulated by 
genes involved in cellular energy metabolism [121, 122, 123, 124] suggesting that 
dexamethasone contributes to the apoptosis / survival decisions in ALL cells indirectly by 
modulating the balance between OXPHOS and glycolysis [15, 120]. Indeed coordination of 
oxidative phosphorylation and glycolysis by mechanisms involving glucocorticoid receptor 
mediated transcriptional regulation of genes encoding enzymes implicated in both 
pathways has been extensively reported in the literature [99, 125, 126]. Enzymes 
participating in the tricarboxylic acid cycle encoded by the nuclear genome such as malate 
dehydrogenase 1 (Mdh1) and succinyl coenzyme A synthetase (Suclg1) are GR 
transcriptional target genes [127]. In addition, several mitochondrial genes encoding 
subunits of the OXPHOS pathway possess one or more functional glucocorticoid responsive 
elements [99, 100, 102, 112, 113] implying that glucocorticoids exert direct effects on 
mitochondrial biogenesis and respiration. Key enzymes involved in glycolysis including 6-
phosphofructo-2-kinase/fructose-2, 6-bisphosphatase [126] lactate dehydrogenase B (LdhB) 
and aldolase A (AldoA) [128] are under GR transcriptional control [120]. 
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To shed light on the molecular mechanisms involved in GR mediated regulation of the 
OXPHOS pathway bioinformatic analysis using the TRED or CCTFSP software [129, 130, 
131] was performed to identify potential glucocorticoid responsive elements (GREs) in the 
promoters of genes encoding Surf-1, and SCO2 enzymes which are essential for the 
assembly of the Cytochrome c Oxidase (COX) wholoenzyme [132, 133, 134]. Similar 
approaches were used to detect possible existence of potential GREs in the regulatory region 
of the promoter of the nuclear gene encoding COX-Va. Putative GREs were identified in the 
regulatory regions of the promoters of Surf-1, SCO2, and COX-Va using this approach. To 
test whether these GREs conferred glucocorticoid responsiveness to the expression of these 
genes, qRT-PCR experiments were performed to quantify their mRNA levels in untreated or 
dexamethasone treated CEM-C1-15 (resistant to glucocorticoid induced apoptosis) and 
CEM-C7-14 (sensitive to glucocorticoid induced apoptosis) ALL cells [135] (Figure 2).  
 
Figure 2. Relative mRNA levels of the COX assembly enzymes Surf-1 (A), SCO-2 (B), and the nuclear 
COX-Va (C) OXPHOS subunit were followed in the resistant CEM-C1-15 and the sensitive CEM-C7-14 
to glucocorticoid induced apoptosis ALL cells treated with dexamethasone for the indicated time points 
by quantitative real-time PCR. Solid lines represent mRNA levels in CEM-C1-15 and dotted lines 
correspond to mRNA levels determined in CEM-C7-14 cells. Error bars represent standard error of the 
mean of five independent experiments and asterisks indicate statistical significance of p<0.05 compared 
to the untreated sample. 
A marked reduction of Surf-1 mRNA levels in the resistant CEM-C1-15 cells was observed 
after 6 and 12 hours of dexamethasone treatment compared to the non-treated cells (Figure 
2A, solid line). In contrast, in the sensitive to glucocorticoid-induced apoptosis CEM-C7-14 
cells, Surf-1 mRNA levels remained constant during the first 6 hours of dexamethasone 
treatment and a moderate increase of Surf-1 mRNA levels was observed only 12h after the 
addition of the hormone (Figure 2A, dotted line). SCO-2 mRNA levels initially increased 
after 3h and 6h of dexamethasone treatment in CEM-C1-15 cells and later after 12h of 
dexamethasone treatment decreased to the level of that exhibited in the untreated cells 
(Figure 2B, solid line). 
The fact that COX-Va expression is altered in various tumours and its association with 
Surf-1 in the formation of sub-complexes consisting of variable COX subunits such as 
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COX-I, COX-II, COX-III, and COX-IV [136] triggered our interest to investigate the 
regulation of the expression of the COX-Va gene. This investigation aimed to test whether 
differential COX-Va cellular levels in the resistant versus the sensitive CEM cells in 
response to glucocorticoid treatment was taking place in a similar way as that observed 
for Surf-1. COX-Va mRNA levels were higher in CEM-C7-14 compared to those detected 
in the CEM-C1-15 cells in all time points of dexamethasone treatment investigated in this 
study and the longer the incubation with the hormone the higher the COX-Va mRNA 
levels in the CEM-C7-14 cells (Figure 2C, compare dotted to solid line). Results shown in 
Figure 2A, 2B, and 2C support the notion that the Surf-1 and COX-Va genes encoded by 
the nuclear genome are under GR transcriptional control and their expression is higher in 
the sensitive to glucocorticoid induced apoptosis cells compared to the resistant CEM-C1-
15 cells. 
 
 
Figure 3. Western blot analysis of Surf-1, SCO-2, and COX-Va in CEM-C1-15 (A) and CEM-C7-14 (B) 
cells treated with dexamethasone for the indicated times. Actin was used as a loading control. 
Densitometric analysis of the western blots presented in A and B was carried out using Image J 
software. The intensity of the bands of Surf-1 (C), SCO2 (D) and COX-Va (E) at each time point was 
normalised to the intensity of the actin band at the respective time point and the obtained values were 
plotted. The intensity of the bands in the untreated cells normalised to the intensity of the actin band in 
the untreated cells was arbitrarily set to 100. The values representing the intensities of the bands in the 
treated cells were calculated as follows: Intensity of band in treated cells/intensity of actin band in 
treated cells x 100 / intensity of band in untreated cells/intensity of actin in untreated cells. Black bars 
represent the CEM-C1-15 cells and the grey bars the CEM-C7-14 cells.  
The protein levels of Surf-1, SCO2 and COX-Va were also followed in CEM-C7-14 and CEM-
C1-15 cells under the same conditions (Figure 3). Higher Surf-1 protein levels were observed 
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in dexamethasone treated CEM-C7-14 cells compared to the non-treated cells for all time 
points tested (Figure 3A, B and C compare grey bars 2, 3 and 4 to grey bar 1). In contrast 
lower Surf-1 protein levels were observed in the dexamethasone treated CEM-C1-15 cells 
irrespectively of the length of the dexamethasone treatment compared to the untreated cells 
(Figure 3A, B and C compare black bars 2, 3 and 4 to black bar 1). In a similar manner to that 
observed for Surf-1, increasing SCO2 protein levels were observed in CEM-C7-14 cells 
treated with dexamethasone for 12h and 24h compared to the untreated cells (Figure 3A, B 
and D compare grey bars 2 and 3 to bar 1). On the contrary lower SCO2 protein levels were 
observed in CEM-C7-14 cells 36h after the addition of dexamethasone compared to the 
untreated cells (Figure 3A, B and D compare grey bar 4 to grey bar 1). On the other side the 
SCO2 protein levels in CEM-C1-15 cells were lower than those measured in the untreated 
cells for all the time points of dexamethasone treatment examined in this study (Figure 3A, 
B and D compare black bars 2, 3 and 4 to black bar 1). Finally the COX-Va protein levels 
were higher in both CEM-C1-15 and CEM-C7-14 cells treated with dexamethasone 
compared to the non-treated cells (Figure 3A, B and E compare black and grey bars 2, 3, and 
4 to grey and black bars 1).  
The expression of COX subunits and oxidative phosphorylation are affected by 
glucocorticoid treatment [137] possibly through the GR transcriptional activity. Given that 
some OXPHOS subunits are encoded by the nuclear genome, and others by the 
mitochondrial DNA, it was thought that glucocorticoids exert indirect effects on the 
regulation of transcription of mitochondrial encoded OXPHOS subunits by modulating the 
activity of nuclear factors involved in the gene expression of mitochondrial genes [101]. 
However, the identification of mitochondrial GR, and the existence of GRE-like domains in 
the mitochondrial genome [100, 101, 138] suggest that glucocorticoids exert direct effects on 
mitochondrial transcription. Taking into consideration the fact that glucocorticoid receptor 
potentially regulates the expression of several COX assembly factors and nuclear COX 
subunits (Figure 2A, 2B and 2C) it was interesting to investigate whether GR fine tunes the 
expression of OXPHOS genes in both nuclear and mitochondrial genomes. In order to assess 
this hypothesis, and in parallel, to strengthen the perception that energy metabolism is a 
possible pathway by which CEM cells determine resistance / sensitivity to glucocorticoid 
induced apoptosis we followed the mRNA levels of the mitochondrial OXPHOS subunits 
COX-I, COX-II and COX-III in CEM C1-15 and CEM C7-14 cells treated with dexamethasone 
(Figures 4A, 4B and 4C). 
A similar picture to that observed for the nuclear OXPHOS components was observed for 
the mitochondrial OXPHOS subunits. Specifically higher cellular levels of the 
mitochondrial COX-I, COX-II and COX-III OXPHOS subunits were observed in CEM-C7-
14 compared to CEM-C1-15 cells (Figure 4A-4C). Increased levels of COX-I mRNA in both 
cell lines after 12 hours of dexamethasone treatment were observed in both CEM-C1-15 
and CEM-C7-14 cells (Figure 4A, compare solid with dotted line). COX-II mRNA 
expression initially decreased in both cell lines 3h after the addition of dexamethasone 
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(Figure 4B, compare solid and dotted lines 3h point) and then started to increase steadily 
at 6 and 12h after the treatment with the hormone but it reached higher levels in the CEM-
C7-14 cells (Figure 4B, compare solid line with dotted line). COX-III gene expression 
remains unaffected by glucocorticoid treatment during the first 3 hours, in CEM-C1-15 
cells, followed by two fold increase 6h and 12h after hormone addition (Figure 4C, solid 
line compare 0 time point with 6 and 12h time points). A similar pattern was evident in 
CEM-C7-14 cells where the induction of COX-III mRNA after 6h and 12h of 
dexamethasone treatment was four and five fold higher respectively compared to those 
detected in the untreated cells (Figure 4C, dotted line compare 0 time point with 6 and 
12h time points). 
 
Figure 4. Relative mRNA levels of the mitochondrial OXPHOS subunits COX-I (A), COX-II (B), and 
COX-III (C) were followed in the resistant CEM-C1-15 and the sensitive CEM-C7-14 to glucocorticoid 
induced apoptosis ALL cells treated with dexamethasone for the indicated time points by quantitative 
real-time PCR. Solid lines represent mRNA levels in CEM-C1-15 and dotted lines correspond to mRNA 
levels determined in CEM-C7-14 cells. Error bars represent standard error of the mean of five 
independent experiments and asterisks indicate statistical significance of p<0.05 compared to the 
untreated sample. 
Taken together, results presented in this manuscript endorse the hypothesis that the 
glucocorticoid resistance / sensitivity in CEM cells is determined by differences in the 
efficacy of the OXPHOS system to produce energy in the two cell lines. Support to this 
conclusion is lent by observations shown in Figure 2A, 2B and 2C indicating that the mRNA 
levels of nuclear encoded components of the OXPHOS system were higher in the sensitive 
CEM-C7-14 than in the resistant CEM-C1-15 cells. Higher levels of COX assembly factors in 
CEM-C7-14 cells imply a more efficient energy metabolism in these cells. This could be a 
result of distinct signalling pathways operating in the two cell lines giving rise to increased 
transactivation function of GR in CEM-C7-14 cells, where the receptor could be 
phosphorylated at S211 [58] and stimulate the expression of its potential transcription 
targets Surf-1 and COX-Va, whereas on the contrary, it is phosphorylated at S226 in CEM-
C1-15 cells, thereby targeted to different subset of its transcriptional targets in these cells 
[58]. The link between altered metabolism in cancer cells and varying expression of COX 
subunits has been well established [139, 140, 141]. The presence of mitochondrial GR and of 
GRE-like domains in the mitochondrial genome [100, 102, 138, 142, 143, 144] and regulation 
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of the mitochondrial COX subunits (COX-I, COX-II and COX-III) provide a probable 
mechanism explaining the dexamethasone dependent regulation of the mitochondrial COX 
subunits gene expression (Figure 4). In addition, differences in post translational 
modifications of the receptor, which in the case of CEM-C7-14 cells, allow activation [58] 
and possibly translocation of GR into mitochondria [96] while in CEM-C1-15 cells these 
events are not permissible could be an additional justification for these observations.  
8. Conclusions and future perspectives  
Resistance to glucocorticoid induced apoptosis in ALL has been attributed to several 
different processes and pathways including predominance of certain GR isoforms with 
reduced transcriptional activity [34, 145, 146], either due to altered binding capacity of the 
receptor to other transcription factors [147, 148, 149, 150] or co-regulators [81, 151], disparate 
expression and consequent dissimilar balance between pro- versus anti-apoptotic members 
of the Bcl-2 family [18], GR mitochondrial localisation [97], autophagy [72, 73, 74, 75], and 
post-translational modifications which affect GR transcription target selectivity and protein 
stability [22, 38, 89, 152, 153].  
We have recently presented evidence to suggest that differential GR phosphorylation in 
resistant versus sensitive to glucocorticoid induced apoptosis ALL cells results in selective 
induction of anti-apoptotic and inhibition of pro-apoptotic Bcl-2 family members gene 
expression in the resistant cells [58]. Several reports have indicated the potential role of 
differential kinase activity in glucocorticoid resistant and sensitive cells in determining the 
GR subcellular localisation [96, 98, 154] and diverse effects on the induction of autophagy 
[72, 73, 74]. 
In this study we provide new evidence signifying the differential expression of OXPHOS 
components in glucocorticoid resistant versus sensitive ALL cells and we propose that 
resistant and sensitive CEM cells use different pathways to produce energy. These results are 
in accord with reports showing that resistance to GC in ALL is associated with increased 
glucose consumption [155] with concomitant induction of Mcl-1 expression and resistance to 
apoptosis [39]. In our anticipated model (Figure 5) in resistant lymphocytes the predominantly 
phosphorylated at S226 GR is possibly transcriptionally inactive and thus incapable to 
significantly induce OXPHOS assembly enzymes and COX subunits gene expression or 
translocate into mitochondria thereby exhibiting reduced oxidative phosphorylation consistent 
with a proliferative phenotype, and this is probably one of the mechanisms employed by the 
glucocorticoid-resistant CEM-C1-15 cells to survive GC treatment.  
The results presented in this study endorse the hypothesis that differential GR 
phosphorylation affects components of cellular energy production pathways in distinct 
ways in resistant versus sensitive cells altering energy production and possibly ROS 
generation in unique ways in the two cell lines, suggesting that combination of kinase 
inhibitors, and glycolytic modulators together with dexamethasone could be a possible 
mean by which resistance to glucocorticoid induced apoptosis could be circumvented in 
ALL. 
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Figure 5. Model summarising the proposed mechanism determining resistance / sensitivity of CEM 
cells to glucocorticoid-induced apoptosis. Differential phosphorylation of GR in glucocorticoid resistant 
versus sensitive cells leads to the reduction of gene expression of OXPHOS subunits and pro-apoptotic 
Bcl-2 family members in the resistant cells (left panel) whereas the opposite is the case for the sensitive 
cells (right panel). 
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